Pharmacotherapy in sickle cell disease—state of the art and future prospects. (отваря нов прозорец)

Hankins J, Aygun B.

Източник‎: Br J Haematol 2009;145(3):296-308.

Статията е индексирана‎: PubMed 19222472

DOI‎: 10.1111/j.1365-2141.2009.07602.x

https://www.ncbi.nlm.nih.gov/pubmed/19222472 (отваря нов прозорец)

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. (отваря нов прозорец)

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Източник‎: Blood 2005;106(7):2269-75.

Статията е индексирана‎: PubMed 16172253

DOI‎: 10.1182/Blood-2004-12-4973

https://www.ncbi.nlm.nih.gov/pubmed/16172253 (отваря нов прозорец)

Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa. (отваря нов прозорец)

John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE

Източник‎: N Engl J Med 2020;382(26):2524-33.

Статията е индексирана‎: PubMed 32579813

DOI‎: 10.1056/NEJMoa2000146

https://www.ncbi.nlm.nih.gov/pubmed/32579813 (отваря нов прозорец)

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. (отваря нов прозорец)

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Източник‎: Br J Haematol 2013;161(6):852-60.

Статията е индексирана‎: PubMed 23590693

DOI‎: 10.1111/bjh.12323

https://www.ncbi.nlm.nih.gov/pubmed/23590693 (отваря нов прозорец)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. (отваря нов прозорец)

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Източник‎: Arch Dis Child 2013;98(11):908-14.

Статията е индексирана‎: PubMed 23995076

DOI‎: 10.1136/archdischild-2012-302387

https://www.ncbi.nlm.nih.gov/pubmed/23995076 (отваря нов прозорец)

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. (отваря нов прозорец)

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Източник‎: Pediatrics 2008;122(6):1332-42.

Статията е индексирана‎: PubMed 19047254

DOI‎: 10.1542/peds.2008-0441

https://www.ncbi.nlm.nih.gov/pubmed/19047254 (отваря нов прозорец)

Impact of hydroxyurea on clinical events in the BABY HUG trial. (отваря нов прозорец)

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Източник‎: Blood 2012;120(22):4304-10.

Статията е индексирана‎: PubMed 22915643

DOI‎: 10.1182/blood-2012-03-419879

https://www.ncbi.nlm.nih.gov/pubmed/22915643 (отваря нов прозорец)

Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. (отваря нов прозорец)

Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators

Източник‎: N Engl J Med 2019;380(2):121-31.

Статията е индексирана‎: PubMed 30501550

DOI‎: 10.1056/NEJMoa1813598

https://www.ncbi.nlm.nih.gov/pubmed/30501550 (отваря нов прозорец)

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. (отваря нов прозорец)

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Източник‎: J Pediatr 2002;140(2):225-9.

Статията е индексирана‎: PubMed 11865275

DOI‎: 10.1067/mpd.2002.121383

https://www.ncbi.nlm.nih.gov/pubmed/11865275 (отваря нов прозорец)

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. (отваря нов прозорец)

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Източник‎: Pediatrics 2013;132(4):677-83.

Статията е индексирана‎: PubMed 23999955

DOI‎: 10.1542/peds.2013-0333

https://www.ncbi.nlm.nih.gov/pubmed/23999955 (отваря нов прозорец)

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). (отваря нов прозорец)

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Източник‎: Lancet 2011;377(9778):1663-72.

Статията е индексирана‎: PubMed 21571150

DOI‎: 10.1016/S0140-6736(11)60355-3

https://www.ncbi.nlm.nih.gov/pubmed/21571150 (отваря нов прозорец)

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. (отваря нов прозорец)

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

Източник‎: Lancet 2016;387(10019):661-70.

Статията е индексирана‎: PubMed 26670617

https://www.ncbi.nlm.nih.gov/pubmed/26670617 (отваря нов прозорец)

How I use hydroxyurea to treat young patients with sickle cell anemia. (отваря нов прозорец)

Ware RE.

Източник‎: Blood 2010;115(26):5300-11.

Статията е индексирана‎: PubMed 20223921

DOI‎: 10.1182/blood-2009-04-146852

https://www.ncbi.nlm.nih.gov/pubmed/20223921 (отваря нов прозорец)

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. (отваря нов прозорец)

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Източник‎: Blood 2004;103(6):2039-45.

Статията е индексирана‎: PubMed 14630791

DOI‎: 10.1182/blood-2003-07-2475

https://www.ncbi.nlm.nih.gov/pubmed/14630791 (отваря нов прозорец)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (отваря нов прозорец)

Hirst C, Owusu-Ofori S.

Източник‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Статията е индексирана‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (отваря нов прозорец)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (отваря нов прозорец)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Източник‎: Lancet Haematol 2021;8(5):e323-33.

Статията е индексирана‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (отваря нов прозорец)

Sickle cell disease. (отваря нов прозорец)

Meremikwu MM, Okomo U.

Източник‎: BMJ Clin Evid 2011;02:2402.

Статията е индексирана‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (отваря нов прозорец)

A phase 3 trial of l-glutamine in sickle cell disease. (отваря нов прозорец)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Източник‎: N Engl J Med 2018;379(3):226-35.

Статията е индексирана‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (отваря нов прозорец)

Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. (отваря нов прозорец)

Olupot-Olupot P, Tomlinson G, Williams TN, Tshilolo L, Santos B, Smart LR, McElhinney K, Howard TA, Aygun B, Stuber SE, Lane A, Latham TS, Ware RE

Източник‎: Blood. 2023 23;141(12):1402-10.

Статията е индексирана‎: PubMed 36375125

DOI‎: 10.1182/blood.2022017051

https://pubmed.ncbi.nlm.nih.gov/36375125/ (отваря нов прозорец)

Malaria chemoprophylaxis in sickle cell disease. (отваря нов прозорец)

Oniyangi O, Omari AA.

Източник‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Статията е индексирана‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (отваря нов прозорец)